Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BVA-202
- Development stage
- Preclinical
- Lead developer
- Biovista
- Modality
- Small Molecules
01
Overview
BVA-202 is a small molecule, repositioned drug candidate developed by Biovista for the treatment of Friedreich's Ataxia (FRDA). As a repositioned drug, it is a previously approved compound being developed for a new indication. BVA-202 functions by targeting oxidative stress pathways, which are central to the pathogenesis of FRDA. In preclinical studies, BVA-202 demonstrated statistically significant results in protecting primary human fibroblasts from FRDA patients against oxidative insult, outperforming idebenone. Additionally, it has shown protective effects in YG8R FRDA mouse cells against oxidative stress induced by iron and buthionine sulfoximine (BSO). The drug is currently in the preclinical stage of development.
Beyond the preview
Go deeper on BVA-202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BVA-202.